Neurocritical Care News

The FDA has granted breakthrough device designation for CT-155, an investigational prescription digital therapeutic co-developed by Click Therapeutics and Boehringer Ingelheim to treat negative symptoms of schizophrenia.

In a cohort of older adults, those with the highest percentage of high-density lipoprotein cholesterol had a 27% higher risk of incident dementia, with the risk higher for those aged 75 years and older, according to a study.

Oragenics Inc. has announced the completion of its acquisition of assets related to Odyssey Health Inc., including its proprietary neurological drug therapies and technologies.

A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.

Healio Neurology looks back at the most-viewed stories throughout the year. Highlights include the FDA’s approval of Leqembi to treat Alzheimer’s disease and the regulatory body’s clearing of a blood test for concussions.

Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.

The FDA has granted regulatory approval for Wainua for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, according to a press release.

A committee of the European Medicines Agency has recommended marketing authorization for Skyclarys to treat Friedreich’s ataxia in patients aged 16 years and older.

Delix Therapeutics announced it has received a $320,000 grant from NIH’s National Institute on Drug Abuse to advance its novel, non-hallucinogenic neuroplastogen for treatment of substance use disorders, including opioid and stimulant use.

The first two female pediatric patients with Rett syndrome have been dosed in an ongoing phase 1/2 trial of investigational AAV9 gene therapy NGN-401, according to the manufacturer.